TORONTO -- A substantial proportion of multiple myeloma patients undergoing treatment with bispecific antibodies had sustained remissions when they discontinued therapy before disease progression, ...
Hospitals are reporting significant success in treating multiple myeloma, with patients undergoing advanced therapies, ...
Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at near ...
Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...
Multiple myeloma is a blood cancer affecting plasma cells, causing abnormal antibody production and bone damage. Diagnosis involves blood tests, bone marrow biopsy, imaging, and genetic analysis to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results